Swiss Life Asset Management Ltd Buys 5,905 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Swiss Life Asset Management Ltd boosted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 17.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,231 shares of the medical equipment provider’s stock after acquiring an additional 5,905 shares during the quarter. Swiss Life Asset Management Ltd’s holdings in Zimmer Biomet were worth $3,864,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Dodge & Cox boosted its stake in shares of Zimmer Biomet by 12.9% during the 2nd quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock worth $2,015,510,000 after acquiring an additional 2,533,009 shares during the period. Norges Bank acquired a new stake in Zimmer Biomet during the second quarter worth approximately $225,867,000. AQR Capital Management LLC boosted its holdings in shares of Zimmer Biomet by 276.6% during the second quarter. AQR Capital Management LLC now owns 1,300,593 shares of the medical equipment provider’s stock worth $118,627,000 after acquiring an additional 955,284 shares during the period. Capital International Investors grew its position in shares of Zimmer Biomet by 11.5% in the third quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock valued at $743,749,000 after purchasing an additional 778,467 shares during the last quarter. Finally, Invesco Ltd. grew its position in shares of Zimmer Biomet by 11.5% in the second quarter. Invesco Ltd. now owns 4,606,591 shares of the medical equipment provider’s stock valued at $420,167,000 after purchasing an additional 475,921 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. TD Cowen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Monday, January 26th. Evercore raised shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and boosted their target price for the company from $94.00 to $120.00 in a research report on Monday, January 5th. Citigroup reaffirmed a “buy” rating on shares of Zimmer Biomet in a research report on Wednesday, February 11th. Robert W. Baird reiterated a “neutral” rating and issued a $100.00 price objective (down from $117.00) on shares of Zimmer Biomet in a research note on Tuesday, December 16th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $106.20.

Zimmer Biomet Stock Performance

Shares of NYSE:ZBH opened at $88.04 on Monday. Zimmer Biomet Holdings, Inc. has a 1 year low of $84.59 and a 1 year high of $114.44. The stock has a market capitalization of $17.23 billion, a price-to-earnings ratio of 24.87, a price-to-earnings-growth ratio of 1.79 and a beta of 0.58. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10. The company’s 50 day simple moving average is $92.12 and its 200 day simple moving average is $94.59.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The firm had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. During the same quarter last year, the business posted $2.31 EPS. The company’s revenue was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. Zimmer Biomet’s payout ratio is 27.12%.

Insider Activity

In related news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the transaction, the senior vice president directly owned 10,224 shares in the company, valued at $967,803.84. This represents a 20.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.70% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.